tweenvest

IMPACT Therapeutics, Inc (SEHK: 7630)

Health Care · Biotechnology · CN

HK$9.12

+8.64% today · -78.2% 1Y

Public summary
A free snapshot of IMPACT Therapeutics, Inc, with figures as of Nov 15, 2026. The full analysis is in the app.Open in the app

IMPACT Therapeutics, Inc (SEHK: 7630) operates in the Biotechnology industry within the Health Care sector. The company is valued at $328.17M and employs 88 people.

Over the last twelve months the share price has lost 78.2%, trading between 7.87 and 47.98.

Tweenvest scores IMPACT Therapeutics, Inc across four factors: quality 42/100, value 70/100. Its strongest factor is value.

7630 price history

May 15, 2026 · 40.04Weekly closes 8.51 – 40.04Nov 13, 2026 · 9.12

Key figures

Market cap
$328.17M
Revenue (TTM)
$17.40M
P/E
-9.27
EPS
-1.44
Dividend yield
—
Beta (5Y)
—
52-week high
HK$47.98
52-week low
HK$7.87
Avg volume (3M)
—
Shares outstanding
282.46M
Employees
88
Next earnings
—

About IMPACT Therapeutics, Inc

IMPACT Therapeutics, a biotechnology firm, specializes in the discovery and advancement of precision anti-cancer treatments rooted in synthetic lethality, operating across China and international markets. The company's primary offering, Senaparib (IMP4297), is a PARP1/2 inhibitor currently deployed as a first-line maintenance therapy for ovarian cancer. Beyond this, Impact Therapeutics maintains a robust pipeline of investigational drugs. This includes IMP1734, a next-generation PARP1 selective inhibitor undergoing Phase I/II trials as a standalone treatment for advanced solid tumors. Another promising candidate is IMP9064, an ATR kinase selective inhibitor, also in Phase I/II clinical studies for advanced solid tumors as a monotherapy. IMP1707, a PARP1 selective inhibitor capable of penetrating the central nervous system, is in Phase I development for homologous recombination repair-deficient tumors. Additionally, IMP7068, an advanced WEE1 inhibitor, is progressing through Phase I/II clinical trials for various advanced solid tumors. Furthermore, a range of other compounds, namely IMP22, IMP25, IMP08, IMP13, IMP10, IMP27, and IMP32, are in the preclinical development phase. The company, established in 2009, is headquartered in Shanghai, China.

ISIN
CNE100007LG4
Founded
2009
Listed since
May 13, 2026
Exchange
The Stock Exchange of Hong Kong Ltd.
Currency
HKD
CompanyMarket capPriceDay
Laekna, Inc.SEHK: 2105$338.09MHK$6.23-5.82%
BioNote, Inc.KOSE: A377740$336.90M₩4,450.00-0.89%
BioDlink International Company LimitedSEHK: 1875$333.92MHK$3.39+1.50%
Xinjiang Tianshan Animal Husbandry Bio-engineering Co., Ltd.SZSE: 300313$330.80MCN¥9.20-3.97%
GC Corp.KOSE: A005250$325.65M₩9,580.00-1.44%
Eikon Therapeutics, Inc.NasdaqGS: EIKN$324.03M$5.98-0.99%
Enanta Pharmaceuticals, Inc.NasdaqGS: ENTA$320.09M$10.99-1.87%
X4 Pharmaceuticals, Inc.NasdaqCM: XFOR$318.59M$3.12-1.58%

Browse every Biotechnology company →